KatherineMeng Ph.D. (Kate)

Associate

芝加哥 + 1.312.269.4395

联系：

Share

Dr. Katherine Meng represents pharmaceutical and biotech companies on the procurement and protection of intellectual property. Kate prosecutes patents and manages patent portfolios worldwide for clients and coordinates strategies to meet clients' IP needs and business goals. She also advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals.

Kate has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapy (e.g., antibodies, antibody drug conjugates, vaccines, cell-based therapies, CAR-T cell technology, and immune checkpoint modulators), gene therapy, cancer treatment, virology, stem cells, neurological disorder therapeutics, diagnostic assays, and therapeutic polypeptides.

Prior to joining Jones Day in 2020, Kate obtained her Ph.D. in molecular cell and developmental biology. She has authored several peer-reviewed publications and has served in several leadership roles throughout her academic studies.

经验

  • Laekna develops global patent portfolios related to various antibody and small molecule drug therapiesJones Day is representing Laekna, Inc. in connection with the development of global patent portfolios related to novel therapeutic antibody and small molecule drug candidates for use in the treatment of various disorders, including cancer, liver fibrosis, and metabolic diseases.
  • VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeabilityJones Day is representing VST Bio Corp. in connection with the establishment of a global patent portfolio related to antibodies that target syndecan-2 and uses thereof in the treatment of diseases related to vascular permeability and leakage, including ischemic stroke and myocardial infarction.
  • Engage Bio develops global patent portfolio related to mRNA-encoded multi-specific binding moleculesJones Day is representing Engage Biologics, Inc. in connection with the development of a global patent portfolio related to methods of treating disease using mRNAs that encode certain multi-specific binding molecules.
    •

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice